Metastatic Refractory
Showing 1 - 25 of >10,000
Pancreatic Cancer, Metastatic Pancreatic Cancer Trial in Tucson (Cabozantinib + Atezolizumab)
Recruiting
- Pancreatic Cancer
- Metastatic Pancreatic Cancer
- Cabozantinib + Atezolizumab
-
Tucson, ArizonaUniversity of Arizona Cancer Center
Dec 14, 2022
Gastrointestinal Cancer Trial in Xuzhou (BGT007 Injection)
Recruiting
- Gastrointestinal Cancer
- BGT007 Injection
-
Xuzhou, JangSu, Chinahe Affiliated Hospital of Xuzhou Medical University
Oct 23, 2023
NSCLC (NSCLC) Trial (Alirocumab and Cemiplimab)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- Alirocumab and Cemiplimab
- (no location specified)
Jan 31, 2023
Digestive Tract Cancer Trial in Xuzhou (BGT007H Injection)
Recruiting
- Digestive Tract Cancer
- BGT007H Injection
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Oct 23, 2023
Refractory Metastatic Colorectal Cancer Trial in Berlin (Radiofrequency electromagnetic field treatment)
Recruiting
- Refractory Metastatic Colorectal Cancer
- Radiofrequency electromagnetic field treatment
-
Berlin, GermanyCharité Universitätsmedizin Berlin
Aug 3, 2023
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite
Completed
- Metastatic Colorectal Adenocarcinoma
- regorafenib plus anti-PD-1 antibodies
-
Changsha, Hunan, ChinaHunan Cancer hospital
Jul 4, 2023
NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors Trial in Belgium, Netherlands, United Kingdom (LNP3794)
Active, not recruiting
- NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
-
Brussels, Belgium
- +3 more
Dec 24, 2021
Pancreatic Cancer Metastatic Trial (C3 (Metformin, Simvastatin, and Digoxin))
Not yet recruiting
- Pancreatic Cancer Metastatic
- C3 (Metformin, Simvastatin, and Digoxin)
- (no location specified)
Sep 1, 2023
Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal
Completed
- Colorectal Cancer
- Fruquintinib combined with anti-PD-1 antibodies
-
ChangSha, Hunan, ChinaHunan Cancer Hospital
Aug 27, 2023
Trifluridine/Tipiracil Plus Bevacizumab Versus
Completed
- Metastatic Colorectal Adenocarcinoma
-
Changsha, Hunan, ChinaHunan Cancer hospital
May 11, 2023
Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma Trial in Seattle
Recruiting
- Metastatic Leiomyosarcoma
- +17 more
- Itacitinib
- Laboratory Biomarker Analysis
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 13, 2022
Refractory Soft Tissue Sarcomas Trial run by the NCI (Cabozantinib)
Active, not recruiting
- Refractory Soft Tissue Sarcomas
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 5, 2022
Tumor Infiltrating Lymphocytes Trial (Autologous tumor-infiltrating lymphocytes)
Not yet recruiting
- Tumor Infiltrating Lymphocytes
- Autologous tumor-infiltrating lymphocytes
- (no location specified)
Nov 28, 2021
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in
Not yet recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +4 more
- Rigosertib
- +4 more
-
Nashville, TennesseeVanderbilt University/Ingram Cancer Center
Feb 28, 2023
Locally Advanced or Metastatic Radioiodine-Refractory
Recruiting
- Thyroid Neoplasms
- Anlotinib Hydrochloride Capsule
-
Beijing, Beijing, China
- +2 more
Aug 9, 2023
Non Small Cell Lung Cancer, Metastatic NSCLC, Recurrent Non Small Cell Lung Cancer Trial (Pembrolizumab, GT103)
Not yet recruiting
- Non Small Cell Lung Cancer
- +2 more
- (no location specified)
Jan 12, 2023
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +20 more
- Neoantigen Peptide Vaccine
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Sep 7, 2022
Metastatic Colorectal Cancer Trial in Nanjing (Envafolimab, Trifluridine/Tipiracil, Bevacizumab)
Recruiting
- Metastatic Colorectal Cancer
- Envafolimab
- +2 more
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with Nanjing Medical University
Sep 24, 2023
Triple Negative Breast Cancer Trial in Shanghai (Personalized treatment guided by mini-PDX and RNA sequencing, Nab paclitaxel,
Recruiting
- Triple Negative Breast Cancer
- Personalized treatment guided by mini-PDX and RNA sequencing
- +5 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Apr 18, 2022
Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Pancreatic Cancer Trial run by the NCI (nivolumab, tadalafil, oral
Completed
- Hepatocellular Carcinoma
- +4 more
- nivolumab
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Not yet recruiting
- Anatomic Stage III Breast Cancer AJCC v8
- +4 more
- Biopsy
- +5 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Feb 14, 2023
Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma Trial in Beijing (Anlotinib Hydrochloride
Not yet recruiting
- Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma
- Anlotinib Hydrochloride Capsule and Penpulimab
-
Beijing, Beijing, ChinaYansongLin
Sep 25, 2023